{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-043347","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.543322+00:00","generated_at":"2026-06-04T00:26:15.662511+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Prelude Therapeutics CFO departs; Bryant Lim named interim CFO","bullets":["Laurent Chardonnet ceased as CFO on April 8, 2024; he will consult at $500/hr through Oct 4, 2024.","Bryant D. Lim, current Chief Legal Officer and Secretary, appointed interim CFO.","Chardonnet receives severance of $333,750 (9 months base salary) plus COBRA subsidy.","Consulting fee up to $50,000; Chardonnet's equity awards continue vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-043347","json":"https://secwatch.observer/filing/0000950170-24-043347.json","markdown":"https://secwatch.observer/filing/0000950170-24-043347.md","text":"https://secwatch.observer/filing/0000950170-24-043347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/0000950170-24-043347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/prld-20240408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:26:15.662511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72f4c95e34","claim":"Bryant D. Lim was appointed as interim Chief Financial Officer at Prelude Therapeutics Inc.","evidence_excerpt":"Effective as of the Effective Date, the Board of Directors of the Company appointed Bryant D. Lim, the Company’s Chief Legal Officer and Corporate Secretary, as its interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/0000950170-24-043347-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e5559f06e7","claim":"Laurent Chardonnet departed as Chief Financial Officer at Prelude Therapeutics Inc.","evidence_excerpt":"On April 8, 2024 (the “Effective Date”), Prelude Therapeutics Incorporated (the “Company”) and Laurent Chardonnet, the Company’s Chief Financial Officer, agreed that he will no longer serve as the Company’s Chief Financial Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/0000950170-24-043347-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"agreed that he will no longer serve"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}